ChiCTR2500106475 版本V1.0 版本创建时间2025/07/24 10:32:36 中国临床试验注册中心

审核状态:

Project audit state:

通过审核

Successful

注册号:

Registration number:

ChiCTR2500106475 

最近更新日期:

Date of Last Refreshed on:

2025-07-24 10:32:27 

注册时间:

Date of Registration:

2025-07-24 00:00:00 

注册号状态:

补注册

Registration Status:

Retrospective registration

注册题目:

重金属暴露与雄激素脱发的关联性研究

Public title:

A Study on the Association Between Heavy Metal Exposure and Androgenetic Alopecia

注册题目简写:

English Acronym:

研究课题的正式科学名称:

重金属暴露与雄激素脱发的关联性研究

Scientific title:

A Study on the Association Between Heavy Metal Exposure and Androgenetic Alopecia

研究课题代号(代码):

Study subject ID:

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

申请注册联系人:

梁雄顺 

研究负责人:

洪文旭 

Applicant:

Xiongshun Liang 

Study leader:

Wenxu Hong 

申请注册联系人电话:

Applicant telephone:

+86 15219475956

研究负责人电话:

Study leader's
telephone:

+86 13823181990

申请注册联系人传真 :

Applicant Fax:

研究负责人传真:

Study leader's fax:

申请注册联系人电子邮件:

Applicant E-mail:

675627664@qq.com

研究负责人电子邮件:

Study leader's E-mail:

szbloodcenter@hotmail.com

申请单位网址(自愿提供):

Applicant website(voluntary supply):

研究负责人网址(自愿提供):

Study leader's website(voluntary supply):

申请注册联系人通讯地址:

广东省深圳市罗湖区布心路2021号

研究负责人通讯地址:

广东省深圳市罗湖区布心路2021号

Applicant address:

No. 2021, Bu Xin Road, Luohu District, Shenzhen, Guangdong

Study leader's address:

No. 2021, Bu Xin Road, Luohu District, Shenzhen, Guangdong

申请注册联系人邮政编码:

Applicant postcode:

研究负责人邮政编码:

Study leader's postcode:

申请人所在单位:

深圳市慢性病防治中心

Applicant's institution:

Shenzhen Center for Chronic Disease Control

研究负责人所在单位:

深圳市慢性病防治中心

Affiliation of the Leader:

Shenzhen Center for Chronic Disease Control

是否获伦理委员会批准:

Approved by ethic committee:

Yes

伦理委员会批件文号:

Approved No. of ethic committee:

SZCCC-2024-051-01-PJ

伦理委员会批件附件:

Approved file of Ethical Committee:

查看附件View

批准本研究的伦理委员会名称:

深圳市慢性病防治中心伦理委员会

Name of the ethic committee:

Ethics Committee of Shenzhen Center for Chronic Disease Control

伦理委员会批准日期:

Date of approved by ethic committee:

2024-12-20 00:00:00

伦理委员会联系人:

陈琳

Contact Name of the ethic committee:

Chen Lin

伦理委员会联系地址:

广东省深圳市罗湖区布心路2021号

Contact Address of the ethic committee:

No. 2021, Bu Xin Road, Luohu District, Shenzhen, Guangdong

伦理委员会联系人电话:

Contact phone of the ethic committee:

+86 755 25105229

伦理委员会联系人邮箱:

Contact email of the ethic committee:

1207391520@qq.com

研究实施负责(组长)单位:

深圳市慢性病防治中心

Primary sponsor:

Shenzhen Center for Chronic Disease Control

研究实施负责(组长)单位地址:

广东省深圳市罗湖区布心路2021号

Primary sponsor's address:

No. 2021, Bu Xin Road, Luohu District, Shenzhen, Guangdong

试验主办单位(项目批准或申办者):

Secondary sponsor:

国家:

中国

省(直辖市):

广东

市(区县):

Country:

China

Province:

Guangdong

City:

单位(医院):

深圳市慢性病防治中心

具体地址:

广东省深圳市罗湖区布心路2021号

Institution
hospital:

Shenzhen Center for Chronic Disease Control

Address:

No. 2021, Bu Xin Road, Luohu District, Shenzhen, Guangdong

经费或物资来源:

自选课题(自筹)

Source(s) of funding:

Self-selected project (self-raised)

研究疾病:

雄激素脱发  

Target disease:

Androgenetic Alopecia

研究疾病代码:

Target disease code:

研究类型:

观察性研究

Study type:

Observational study

研究所处阶段:

其它 

Study phase:

N/A

研究设计:

病例对照研究 

Study design:

Case-Control study 

研究目的:

(1)建立雄激素脱发患者和健康人血浆中重金属水平的检测方法; (2)探索雄激素脱发与重金属元素之间的关联;  

Objectives of Study:

(1) Establish a method for detecting heavy metal levels in the plasma of patients with androgenetic alopecia and healthy individuals. (2) Explore the association between androgenetic alopecia and heavy metal elements.

药物成份或治疗方案详述:

 

Description for medicine or protocol of treatment in detail:

 

纳入标准:

1.雄激素性脱发的患者。2.年龄>=18岁。3患者充分理解本项目内容并且同意参加。

Inclusion criteria

1.Patients with androgenetic alopecia. 2. Age >= 18 years. 3. Patients fully understand the content of this study and agree to participate.

排除标准:

1. 从未患过雄激素脱发的个人。2. 排除患有其他可能影响雄激素脱发判断的皮肤病患者。3. 个人无法理解或不同意参与本项目。

Exclusion criteria:

1.Individuals who have never had androgenetic alopecia. 2. Exclusion of patients with other skin diseases that may affect the diagnosis of androgenetic alopecia. 3. Individuals who are unable to understand or do not agree to participate in this study.

研究实施时间:

Study execute time:

From 2024-12-01 00:00:00 To 2026-06-01 00:00:00  

征募观察对象时间:

Recruiting time:

From 2024-12-25 00:00:00 To 2025-12-31 00:00:00

干预措施:

Interventions:

组别:

病例组

样本量:

150

Group:

Case group

Sample size:

干预措施:

干预措施代码:

Intervention:

None

Intervention code:

组别:

对照组

样本量:

150

Group:

Control group

Sample size:

干预措施:

干预措施代码:

Intervention:

None

Intervention code:

研究实施地点:

Countries of recruitment and research settings:

国家:

中国

省(直辖市):

广东 

市(区县):

 

Country:

China

Province:

Guangdong

City:

单位(医院):

深圳市慢性病防治中心 

单位级别:

无  

Institution
hospital:

Shenzhen Center for Chronic Disease Control

Level of the institution:

N/A

测量指标:

Outcomes:

指标中文名:

重金属水平(Cd、Fe、Pb、Cr、Cu、As、Ni、Zn)

指标类型:

主要指标

Outcome:

Heavy metal levels(Cd, Fe, Pb, Cr, Cu, As, Ni, Zn)

Type:

Primary indicator

测量时间点:

诊断结束后2周。

测量方法:

采用电感耦合等离子体质谱仪(ICP-MS)检测雄激素脱发患者和健康受试者血浆中的重金属水平

Measure time point of outcome:

Two weeks after diagnosis.

Measure method:

Inductively coupled plasma mass spectrometry (ICP-MS) was used to detect the levels of heavy metals in plasma of androgenetic alopecia patients and healthy subjects

指标中文名:

年龄

指标类型:

次要指标

Outcome:

Age

Type:

Secondary indicator

测量时间点:

诊断当天

测量方法:

体检仪检测、问卷调查

Measure time point of outcome:

Diagnosis day

Measure method:

Physical examination instrument testing、Questionnaire survey

指标中文名:

体质指数

指标类型:

次要指标

Outcome:

Body mass index

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

体重

指标类型:

次要指标

Outcome:

Body weight

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

腰围

指标类型:

次要指标

Outcome:

Waist circumference

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

吸烟

指标类型:

次要指标

Outcome:

Smoking

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

饮酒

指标类型:

次要指标

Outcome:

Drinking alcohol

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

采集人体标本:

Collecting sample(s)
from participants:

标本中文名:

组织:

Sample Name:

N/A

Tissue:

人体标本去向

其它  

说明

Fate of sample:

0thers  

Note:

征募研究对象情况:

Recruiting status:

正在进行

Recruiting

年龄范围:

Participant age:

最小 Min age 18 years
最大 Max age years

性别:

男女均可

Gender:

Both

随机方法(请说明由何人用什么方法产生随机序列):

Randomization Procedure (please state who generates the random number sequence and by what method):

None

是否公开试验完成后的统计结果:

Calculated Results after the Study Completed public access:

不公开/Private

盲法:

Blinding:

None

是否共享原始数据:

IPD sharing

是Yes

共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):

原始数据将在2026年9月,临床研究公共管理平台 ResMan(www.medresman.org)上共享

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url):

The raw data will be shared on ResMan (www.medresman.org), a public repository for clinical research, in September 2026

数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC:

数据采集为电子采集,从原始采集系统调出的有关受试者数据需全部以受试者编码方式记录,受试者只能通过受试者编码识别相关原始检测结果,并安排指定数据管理员对数据库进行锁定,任何数据的调取修正均需经过此项目数据管理员确认后,方可进行下游分析,确保数据安全。所有参与此项目的研究者需保证数据真实、完整、准确。

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:

Data collection is conducted electronically. Data relevant to subjects retrieved from the original collection system must be recorded entirely using subject codes. Subjects can only identify their relevant original test results through their subject codes. A designated data manager is assigned to lock the database. Any data retrieval or correction must be confirmed by the project data manager before downstream analysis can proceed to ensure data security. All researchers involved in this project must guarantee the data's authenticity, integrity, and accuracy.

数据与安全监察委员会:

Data and Safety Monitoring Committee:

有/Yes

注册人:

Name of Registration:

 2025-07-24 10:32:27